RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
1.210
0.00 (0.01%)
At close: Nov 21, 2024, 4:00 PM
1.170
-0.040 (-3.31%)
After-hours: Nov 21, 2024, 4:02 PM EST
RenovoRx Employees
RenovoRx had 8 employees as of December 31, 2023. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,145,375
Market Cap
29.03M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 8 | -1 | -11.11% |
Dec 31, 2022 | 9 | 3 | 50.00% |
Dec 31, 2021 | 6 | -3 | -33.33% |
Dec 31, 2020 | 9 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Allurion Technologies | 504 |
IGC Pharma | 67 |
Athira Pharma | 67 |
MiNK Therapeutics | 31 |
Daré Bioscience | 26 |
Longeveron | 24 |
GeoVax Labs | 17 |
Lipocine | 17 |
RNXT News
- 1 day ago - Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - GlobeNewsWire
- 7 days ago - RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 2 months ago - RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians - GlobeNewsWire
- 2 months ago - RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 3 months ago - RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York - GlobeNewsWire
- 3 months ago - RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - GlobeNewsWire
- 4 months ago - RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist® - GlobeNewsWire
- 5 months ago - University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial - GlobeNewsWire